OTLKNot HalalF
Unlock full report, free

Is Outlook Therapeutics (OTLK) Stock Halal?

Compliance Status

Not Halal

Screened on Nov 6, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Outlook Therapeutics, Inc. (OTLK) halal? Not Halal. Based on AAOIFI screening, Outlook Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Outlook Therapeutics, Inc. (OTLK) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 6, 2026. Source: https://halalscreener.app/en/stock/OTLK

Business activity

What the company sells is permissible.

Passed

Company debt

Close to the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

27.5% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding OTLK

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Share this verdict

A receipt-style image with the math on it, so whoever you send it to can check it.

Outlook Therapeutics, Inc.

OTLK

Outlook Therapeutics, Inc.

NASDAQHealthcareUS

$0.44

Market Cap: 106.2M

Get an email if OTLK's halal status changes

We re-screen Outlook Therapeutics, Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

  • Income from prohibited sources is over the 5% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Nov 6, 2026
AI Compliance InsightProSee plans
Revenue BreakdownProSee plans

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: EDGAR
Free · No credit card required

Know the day OTLK's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Outlook Therapeutics, Inc. (OTLK) halal to invest in?
Outlook Therapeutics, Inc. (OTLK) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Outlook Therapeutics, Inc. get a F compliance rating?
Outlook Therapeutics, Inc. (OTLK) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 27.5% (limit 30%); interest-bearing deposits well clear of the 30% limit; prohibited income over the 5% limit. The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Outlook Therapeutics, Inc.'s Shariah verdict?
Outlook Therapeutics, Inc.'s verdict is recalculated at every re-screen, including the one that follows each new quarterly or annual report. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Outlook Therapeutics, Inc. re-screened for Shariah compliance?
Outlook Therapeutics, Inc. (OTLK) is screened from the latest financial statements on record, currently those for fiscal year 2025. The 500 largest US-listed companies, and every stock on a HalalScreener watchlist or portfolio, are re-screened daily against the current market cap; every other stock at least once a week. When the company files a new quarterly or annual report with the SEC, it is re-screened from that filing: we check the SEC's filing feed every 15 minutes and the earnings calendar every day. Last screened: Nov 6, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.